Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $2.831 million which missed the analyst consensus estimate of $4.065 million by 30.36 percent. This is a 39.22 percent decrease over sales of $4.658 million the same period last year.